ArticleJournal of neurology2025
A pilot study of telitacicept in predominantly immune-mediated necrotizing myopathy, retrospective analysis of a monocentric Chinese cohort.
Article in Journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundIdiopathic inflammatory myopathies (IIM) are a group of rare autoimmune disorders mainly involving skeletal muscles. Telitacicept is a BAFF/APRIL inhibitor, which has a promising application in B-cell-mediated autoimmune diseases; however, its efficacy in IIM patients is still unknown.
methodsRetrospective analysis of 15 IIM patients treated with telitacicept for more than 6 months in Xiangya Hospital between November 2023 and May 2025. Core clinical measures and glucocorticoid (GCS) dosage at baseline, 3 months, 6 months, and final follow-up were recorded. The treatment was evaluated according to the total improvement score (TIS) defined by the 2016 ACR/EULAR myositis response criteria.
resultsIn the final follow-up, 11 patients (73.33%) had improved clinical symptoms after 8 months of median treatment. Significant improvements were observed in physician/patient global assessments (PhGA/PtGA), manual muscle testing (MMT-8), health assessment questionnaire (HAQ) score, and creatine kinase (CK) levels (all p < 0.05). The average GCS dose dropped from 23.67 ± 18.37 to 11.00 ± 11.05 mg/d (p = 0.006). Serum IgG (p = 0.018), IgA (p < 0.001), and IgM (p < 0.001) decreased, while C3 (p = 0.001) and C4 (p = 0.030) increased. No serious drug-related adverse events occurred.
conclusionsTelitacicept may be an effective and safety-promising therapeutic option for IIM, especially IMNM patients. Larger randomized controlled trials are required to confirm these findings.
Indexed as
Identifiers
41379391What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.